BioPharma Resources

NDA 220963 · Rare Thyroid

Emcitate

Tiratricol · Oral

NovelPriority reviewOrphan

CDER novel approval, Sep 28, 2026: To treat peripheral thyrotoxicosis in patients with MCT8 deficiency

Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2026

Sep 28, 2026

Approved uses

1

Original approval plus efficacy supplements

Registered trials

3

1 Phase 3, 0 recruiting

FAERS reports

15

13 serious, 1 with death reported

AI brief across all sources

Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS Thyroid hormones, including EMCITATE, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss [see Warnings and Precautions ( 5.2 )]. WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS See full prescribing information for complete boxed warning. Thyroid hormones, including EMCITATE, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. ( 5.2 )

What it is approved for

From the label in effect Oct 1, 2026.

EMCITATE is indicated for the treatment of peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 (MCT8) deficiency (Allan-Herndon-Dudley syndrome). EMCITATE is a thyroid hormone receptor agonist indicated for the treatment of peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 (MCT8) deficiency (Allan-Herndon-Dudley syndrome). Limitation of Use EMCITATE is not recommended for the treatment of primary hypothyroidism. Limitation of Use EMCITATE is not recommended for the treatment of primary hypothyroidism.

Mechanism: Tiratricol is a thyroid hormone receptor (THR) agonist which, unlike triiodothyronine (T3) and thyroxine (T4), can enter cells independent of the transmembrane transporter protein MCT8. In patients with MCT8 deficiency, X-linked loss-of-function mutations in the SLC16A2 gene encoding MCT8 impair T3 entry into target tissues. This results in insufficient T3 activity in the brain concurrent with persistent peripheral thyrotoxicosis from accumulation of circulating T3. Intracellular tiratricol activity at THR-β, independent of MCT8-mediated membrane transport, can modulate...

Therapeutic areas: Rare and genetic disease

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 28, 2026 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLetterLabel
1 products under this application
  • EMCITATE · TIRATRICOL 350MCG · TABLET, FOR SUSPENSION, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Tiratricol" as an intervention, any sponsor and status, largest first.

All 3 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • apraxia4
  • hypokalaemia4
  • mydriasis4
  • syncope4
  • thyroid disorder4
  • acute coronary syndrome3
  • off label use3
  • alanine aminotransferase increased2
  • cardiac arrest2
  • head injury2
  • intentional product misuse2
  • toxicity to various agents2

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041
20052
20071
20101
20134
20191
20203
20212

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3 on PubMed

Sponsor: Rare Thyroid

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.